Bristol-Myers Squibb Company (BMY)
| Market Cap | 113.53B |
| Revenue (ttm) | 48.03B |
| Net Income (ttm) | 6.04B |
| Shares Out | 2.04B |
| EPS (ttm) | 2.97 |
| PE Ratio | 18.77 |
| Forward PE | 9.03 |
| Dividend | $2.52 (4.52%) |
| Ex-Dividend Date | Jan 2, 2026 |
| Volume | 13,236,818 |
| Open | 56.11 |
| Previous Close | 55.86 |
| Day's Range | 55.51 - 56.59 |
| 52-Week Range | 42.52 - 63.33 |
| Beta | 0.29 |
| Analysts | Buy |
| Price Target | 57.46 (+3.03%) |
| Earnings Date | Feb 5, 2026 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for BMY stock is "Buy." The 12-month stock price target is $57.46, which is an increase of 3.03% from the latest price.
News
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Camzyos--BMS Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic oHCM.
Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 44th Annual Healthcare Conference.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
This Beaten-Down Pharma Stock Could Make a Turnaround in the New Year
At the current price, investors are paying little for Bristol Myers' pipeline.
Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January
Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite...
Bristol-Myers Squibb: Contrarian Buy For Dividend Hunters, Despite Mounting Growth Headwinds
BMY remains a great Buy, supported by the the deeply discounted valuations, the robust cash flows, the healthier balance sheet, and the secure/richer dividend yields. The Growth Portfolio now drives 5...
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over - It's Not
Bristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x. BMY's growth portfolio now generates 57% of total revenue, growing 18% YoY an...
Jenny Harrington's top dividend plays for 2026
Jenny Harrington, CEO Gilman Hill Asset Management, joins CNBC's "Halftime Report" to share her top dividend plays for 2026.
Bristol-Myers Squibb: Pharma Giant Still Undervalued And Printing Cash Despite Patent Cliff
Bristol-Myers Squibb Company has rebounded solidly, as the market finally recognizes prior pessimism was excessive, driving renewed investor interest. Despite an estimated >60% revenue facing loss of ...
Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued
Bristol-Myers Squibb remains a "Buy," driven by robust Q3 results and a positive technical setup heading into 2026. BMY raised FY 2025 guidance, with operating EPS targeted at $6.40–$6.60 and net sale...
3 Top Value Stocks to Buy and Hold for 2026
These high-quality stocks with value characteristics look attractive today.
Bristol-Myers Squibb: Still Undervalued And Generating 4.65% Dividend Yield
Bristol-Myers Squibb (BMY) is transitioning from a perceived value trap to a growth-focused, diversified pharmaceutical company. BMY's growth portfolio grew 18% YoY in Q3, offsetting legacy drug decli...
Final Trade: NCNO, LION, SNAP, BMY
CNBC's “Fast Money” team share their final trades of the day.
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans.
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026.
AbbVie, several other pharma companies near MFN deal with Trump, sources say
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands , Dec. 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of nov...
Final Trade: JNJ, NVO, UBER, BMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Bristol Myers Trades At Trough Valuation — Analyst Says Pipeline Upside Is Being Ignored
BofA Securities upgraded Bristol Myers Squibb & Co. (NYSE: BMY), citing near-term catalysts.